VHL is a genetic systemic condition with the potential for
multi-organ manifestations1
VHL gene mutations predispose patients to the development of cysts and tumors in several systems and organs.1,4
- Cysts and tumors can grow
and negatively affect the
organs and structures
around them.3 - Some tumors, such as those
found in the kidneys and
pancreas, may become
cancerous.3
VHL disease affects 1 in 36,000 live births1
While the average age of VHL onset is 26 years old, manifestations
of the disease can appear in individuals as young as 1 year old.4,6
References: 1. Varshney N, Kebede AA, Owusu-Dapaah H, et al. A review of von Hippel-Lindau syndrome. J Kidney Cancer VHL. 2017;4(3):20–29. 2. Ploussard G, Droupy S, Ferlicot S, et al. Local recurrence after nephron-sparing surgery in von Hippel-Lindau disease. Urology. 2007;70(3):435–439. 3. VHL Alliance. What is VHL? Manifestations. https://www.vhl.org/patients/what-is-vhl/types-and-manifestations. Accessed September 7, 2022. 4. National Organization for Rare Disorders. Von Hippel-Lindau disease. https://rarediseases.org/rare-diseases/von-hippel-lindau-disease/. Accessed September 7, 2022. 5. US Food and Drug Administration. Rare diseases at FDA. https://www.fda.gov/patients/rare-diseases-fda. Accessed September 7, 2022. 6. Ganeshan D, Menias CO, Pickhardt PJ, et al. Tumors in von Hippel–Lindau syndrome: from head to toe—comprehensive state-of-the-art review. RadioGraphics. 2018;38(3):849–866.
Copyright © 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
This site is intended only for residents of the United States, its territories, and Puerto Rico. US-BEL-00491 09/22